Cardiometabolic syndrome and chronic kidney disease

被引：47

作者：

Lastra G. ^{[1
]}

Manrique C. ^{[1
]}

McFarlane S.I. ^{[1
]}

Sowers J.R. ^{[1
]}

机构：

[1] Division of Endocrinology, Department of Medicine, Physiology, and Pharmacology, University of Missouri Health Sciences Center, Columbia, MO 65212, One Hospital Drive

来源：

Current Diabetes Reports | 2006年 / 6卷 / 3期

关键词：

Insulin Resistance; Chronic Kidney Disease; Metabolic Syndrome; Diabetic Nephropathy; Endoplasmic Reticulum Stress;

D O I：

10.1007/s11892-006-0036-5

中图分类号：

学科分类号：

摘要：

Chronic kidney disease (CKD) is increasingly recognized as a major risk factor for end-stage renal disease (ESRD), cardiovascular (CV) disease, and CV-related premature death. More than 8 million people in the United States have CKD; therefore, preventive strategies should be directed at identifying risk factors for this condition. There is growing evidence implicating the cardiometabolic syndrome, a clustering of CV risk factors that include obesity, insulin resistance, compensatory hyperinsulinemia, dysglycemia, atherogenic dyslipidemia, and hypertension. Factors mediating this relationship include increased glomerular filtration, increased vascular permeability, oxidative and endoplasmic reticulum stress, activation of the renin-angiotensin system, and inappropriate secretion of growth factors. The consequences are microalbuminuria, a marker of inflammation and endothelial dysfunction, renal vascular proliferation, extracellular matrix expansion, and CKD. Prevention of CKD should be directed at controlling all components of the cardiometabolic syndrome, with the ultimate goal of reducing the burden imposed by ESRD. Copyright © 2006 by Current Science Inc.

引用

页码：207 / 212

页数：5

共 57 条

[1]

Manrique C., Lastra G., Whaley-Connell A., Sowers J.R., Hypertension and the cardiometabolic syndrome, J Clin Hypertens, 7, pp. 471-476, (2005)

[2]

USRDS 2005 Annual Data Report: Atlas of end-stage renal disease in the United States, (2005)

[3]

El-Atat F., Stas S.N., McFarlane S.I., Sowers J.R., The relationship between hyperinsulinemia, hypertension and progressive renal disease, J Am Soc Nephrol, 15, pp. 2816-2827, (2004)

[4]

K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification, Am J Kidney Dis, 39, (2002)

[5]

Coresh J., Astor B.C., Greene T., Et al., Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey, Am J Kidney Dis, 41, pp. 1-12, (2003)

[6]

Biesenback G., Hubmann R., Grafinder P., Et al., 5-year overall survival rates of uremic type 1 and type 2 diabetic patients in comparison with age-matched nondiabetic patients with end-stage renal disease from a single dialysis center from 1991 to 1997, Diabetes Care, 23, pp. 1860-1862, (2000)

[7]

Chen J., Muntner P., Hamm L.L., Et al., The metabolic syndrome and Chronic Kidney Disease in U.S. Adults, Ann Intern Med, 140, pp. 167-174, (2004)

[8]

Tanaka H., Shiohira Y., Uezu Y., Et al., Metabolic syndrome and chronic kidney disease in Okinawa, Japan, Kidney Int, 69, pp. 369-374, (2006)

[9]

Kurella M., Lo J.C., Chertow G.M., Metabolic syndrome and the risk of chronic kidney disease among nondiabetic adult, J Am Soc Nephrol, 16, pp. 2134-2140, (2005)

[10]

Fliser D., Pacini G., Engelleiter R., Et al., Insulin resistance and hyperinsulinemia are already present in patient with incipient renal disease, Kidney Int, 53, pp. 1343-1347, (1998)

← 1 2 3 4 5 6 →